{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"386"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}],"units":"Participants"}],"groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal","id":"OG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Unstratified intention to treat population","reportingStatus":"POSTED","timeFrame":"within 6.5 years","title":"Participants With Progression Free Survival Event","type":"SECONDARY","unitOfMeasure":"participants"}